linjc16/ctgov huggingface dataset:
Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the performance of a PET/ CT-based deep learning signature for predicting the grade 3 tumors based on the novel grading system in clinical stage stage I lung adenocarcinoma based on a multicenter prospective cohort.

Official Title
-----------------
Deep Learning Signature Based on PET-CT Images for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma

Conditions
-----------------
Lung Adenocarcinoma, Radiomics, Grading System

Intervention / Treatment
-----------------
* Diagnostic Test: PET/CT-based Radiomics Signature


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: (1) Participants scheduled for surgery for radiological finding of pulmonary lesions from the preoperative thin-section CT scans; (2) The maximum diameter of lesion less than 4 cm on CT scans; (3) The maximum short axis diameter of lymph nodes less than 1 cm on CT scan; (4) The SUVmax of hilar and mediastinal lymph nodes less than 2.5; (5) Pathological confirmation of primary lung adenocarcinoma; (5) Age ranging from 20-75 years; (6) Obtained written informed consent. Exclusion Criteria: (1) Multiple lung lesions; (2) Poor quality of PET-CT images; (3) Participants with incomplete clinical information; (4) Mucinous adenocarcinomas; (5) Participants who have received neoadjuvant therapy.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: PET/CT-based Radiomics Signature|Radiomics Signature Based on PET-CT for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area under the receiver operating characteristic curve | Area under the receiver operating characteristic curve | 2022.11-2023.4 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Sensitivity | Sensitivity | 2022.11-2023.4 | 
| Specificity | Specificity | 2022.11-2023.4 | 
| Positive predictive value | Positive predictive value | 2022.11-2023.4 | 
| Negative predictive value | Negative predictive value | 2022.11-2023.4 | 
| Accuracy | Accuracy | 2022.11-2023.4 |
Effects of Footstrike Transition on Tibial Stress Fracture Risk

Study Overview
=================
Brief Summary
-----------------
Biomechanical literature suggests that runners who utilize a mid or forefoot strike pattern may suffer from a reduced incidence of chronic injuries compared to a rearfoot strike. This investigation examined the effects of a 10-week footstrike transition intervention on tibial stress fracture risk in runners.

Official Title
-----------------
Effects of Footstrike Transition on Tibial Stress Fracture Risk Using Musculoskeletal Simulation, Finite Element Analysis and Probabilistic Modelling - a Pilot Study

Conditions
-----------------
Tibial Stress Fracture

Intervention / Treatment
-----------------
* Behavioral: Footstrike modification
* Behavioral: Control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Recreational runner 3-years minimum of running experience Injury free for 12-months Exclusion Criteria: Injury at baseline

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Footstrike modification<br> | Behavioral: Footstrike modification<br> <br> |
| Active Comparator: Control<br> | Behavioral: Control<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stress fracture probability | Probability of stress fracture quantified using a probabilistic modelling approach. | Baseline | 
| Stress fracture probability | Probability of stress fracture quantified using a probabilistic modelling approach. | 10-weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Three-dimensional tibial loading | Forces applied to the tibia, measured using musculoskeletal simulation. | Baseline | 
| Three-dimensional tibial loading | Forces applied to the tibia, measured using musculoskeletal simulation. | 10-weeks | 
| Tibial strain | Strains experienced by the tibial quantified using finite elements analysis. | Baseline | 
| Tibial strain | Strains experienced by the tibial quantified using finite elements analysis. | 10-weeks |
Enhanced Recovery in Esophageal Surgery

Study Overview
=================
Brief Summary
-----------------
Esophageal surgery remains the main treatment for esophageal cancer. Despite constant improvements, morbidity of esophagectomy remains high. For several years, enhanced rehabilitation programs have been used to reduce the impact of surgery on the patients to support a faster recovery. This study analyses the first results of newly implemented enhanced program after esophagectomy within the framework of an academic center.

Official Title
-----------------
Implementation and Early Results on an Enhanced Recovery Program in Esophageal Surgery

Conditions
-----------------
ERAS Protocol, Esophagectomy

Intervention / Treatment
-----------------
* Procedure: Enhanced recovery program


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All consecutive esophagectomy Exclusion Criteria: Contraindication for surgery according to the WHO physical status of IV, emergency surgery, mental illness and patient's refusal.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ERAS group<br> | Procedure: Enhanced recovery program<br>* Recvoery programs includes specific measures validated in multidisciplinary consultation, spread over the pre- intra- and postoperative period.<br>|
| Control group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants who reach the the 23 measurements of the enhanced recovery program | compliance is defined by the achievement of the various items of the rehabilitation program (23 items) | an average of 15 days (During the surgical period (hospital stay) |
Cervical Cancer Screening With NGS-HPV Technology Based on Menstrual Blood

Study Overview
=================
Brief Summary
-----------------
Our study is conducted to recruit cervical cancer screening patients to evaluate the application value of using high-throughput sequencing technology to detect HPV in menstrual blood for cervical cancer screening.

Detailed Description
-----------------
Our study aims to recruit 10,000 cervical cancer screening patients from the outpatient department of Zhongnan Hospital of Wuhan University from September 1, 2023 to March 31, 2028. The procedures were conducted as below: (1) Conduct cervical cancer screening (TCT+cobas-HPV) for all the participants. (2) Collect sanitary napkins from participants during their first menstrual period after cervical HPV testing. (3) Detect HPV using high-throughput sequencing technology in the menstrual blood (MB) from sanitary napkins. (4) Colposcopy referral (biopsy if necessary) for patients with abnormal screening results. (5) Compare the concordance between MB-HPV and cobas-HPV.

Official Title
-----------------
Cervical Cancer Screening With NGS-HPV Technology Based on Menstrual Blood

Conditions
-----------------
Cervical Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: plan to undergo cervical screening with regular menstruation agree to participate in this study and have signed an informed consent form Exclusion Criteria: with amenorrhea or menopause suffering from genital tract infection refuse to participate in this study

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HPV detection in menstrual blood | Exploring the concordance between MB-HPV and cobas-HPV | December 31, 2023 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HPV, menstrual blood, cervical cancer, screening,
Epidemiology of Helicobacter Pylori Infection in Children From Slovenia

Study Overview
=================
Brief Summary
-----------------
The epidemiology of H. pylori infection among children in Slovenia has not been investigated. Therefore, we are conducting a study to examine the epidemiology of H. pylori and associated risk factors among children in Slovenia.

Detailed Description
-----------------
The population selection was from the three different geographic location in Slovenia. The selection of the studied places was based on their social and economic characteristics and medical provision. We included children from three age groups at the same time we collected information from the parents which may be important for H. pylori transmission.

Official Title
-----------------
Epidemiology of Helicobacter Pylori Infection in Children From Slovenia

Conditions
-----------------
Helicobacter Pylori Infection, Transmission

Intervention / Treatment
-----------------
* Other: Prevalence study population


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 6, 14 and 17 years living in three different regions in Slovenia Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Prevalence study population<br>prevalence study population | Other: Prevalence study population<br>* No intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The number of infected children in different age population |  | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
children, infection
Effectiveness and Durability Long-term Results of Tricuspid Annuloplasty With 3D Shaped Rings.

Study Overview
=================
Brief Summary
-----------------
Interest in tricuspid valve disease has grown exponentially over the past few years, in response to increased interest in the poor prognosis of patients with functional tricuspid regurgitation (TR). Tricuspid valve repair (TVR) using a prosthetic ring represents the first option in many centers worldwide, due to the low incidence of residual and recurrent TR and improved survival compared to suture techniques. The goal of ring annuloplasty is to restore the normal geometry of the annulus, thereby improving the coaptation of the leaflets and preventing further dilatation of the annulus. Recently, the three-dimensional geometry of the tricuspid valve has been shown and analyzed by means of data obtained from echocardiography, CT scan and magnetic resonance imaging. Normal tricuspid annulus is characterized by a more prominent part in the anteroseptal commissure area near the aortic valve and right ventricular outflow tract and a deeper part in the posteroseptal commissure area near the coronary sinus ostium . Based on these characteristics, new three-dimensional rings have been developed for tricuspid annuloplasty, such as the MC3 (Edwards Lifescience, Irvine, CA) and the Contour 3D (Medtronic, Minneapolis, MN). There are few studies concerning the short-term results of tricuspid rings implantation and almost none on the long-term, therefore this study aims to analyze the long-term results of TVR by implantation of the two new prosthetic ring models mentioned above. The aim of this study is the long-term analysis of the results of tricuspid annuloplasty with three-dimensional rings in patients with functional IT.

Official Title
-----------------
Effectiveness and Durability Long-term Results of Tricuspid Annuloplasty With 3D Shaped Rings.

Conditions
-----------------
Functional Tricuspid Regurgitation

Intervention / Treatment
-----------------
* Procedure: Tricuspid valve annuloplasty with 3D ring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients Operated for functional TR Implantation of three-dimensional tricuspid prosthetic ring MC3 or Contour 3D, isolated or concomitant to surgery on the left heart sections Surgical access in median sternotomy or minithoracotomy Exclusion Criteria: - emergency/urgency intervention

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Tricuspid valve annuloplasty with 3D ring|A 3D ring is implanted to treat functional tricuspid valve regurgitation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality |  | through study completion, an average of 7 years |
Incretin Effect in Patients With Psoriasis and Controls

Study Overview
=================
Brief Summary
-----------------
To investigate the incretin effect and postprandial incretin responses in plasma in patients with psoriasis

Official Title
-----------------
Incretin Effect in Patients With Psoriasis

Conditions
-----------------
Psoriasis Vulgaris

Intervention / Treatment
-----------------
* Diagnostic Test: Oral glucose tolerance test
* Other: Intravenous isoglycaemic glucose clamp
* Other: Liquid Mixed meal test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: no diabetes BMI < 27 kg/m^2 normal Glucose tolerance test at screening normal fasting plasma glucose no islet auto antibodies no hormonel contraception informed consent psoriasis vulgaris (PASI>8) (case not controls) Exclusion Criteria: other chronic inflammtory skin disease other chronic inflammatory disease pregnancy psychiatric illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Psoriasis<br> | Diagnostic Test: Oral glucose tolerance test<br>* Oral glucose tolerance test 50g<br>Other: Intravenous isoglycaemic glucose clamp<br>* Intravenous isoglycaemic glucose clamp<br>Other: Liquid Mixed meal test<br>* Liquid Mixed meal test 520 kcal<br>|
| Control<br>Age, Sex and BMI matched | Diagnostic Test: Oral glucose tolerance test<br>* Oral glucose tolerance test 50g<br>Other: Intravenous isoglycaemic glucose clamp<br>* Intravenous isoglycaemic glucose clamp<br>Other: Liquid Mixed meal test<br>* Liquid Mixed meal test 520 kcal<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incretin effect measured with Beta-cell secretory response | Incretineffect (%) = 100 % × (Beta-cell Secretory Response (OGTT) - Beta-cell Secretory Response (IIGI)) / Beta-cell Secretory Response (OGTT) | 0-180 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Insulin sensitivity measures | Matsudas insulin sensitivity index: (10,000 / √glucose minute 0 x insulin minute 0) (mean glucose (OGTT) x mean insulin OGTT)) | 0-180 minutes | 
| Concentration of Glucose-independent insulinotropic polypeptide | Evaluted as Area Under the Curve | 0-180 minutes | 
| Concentration of Glucagon-like peptide 1 | Evaluated as Area Under the Curve | 0-180 minuntes | 
| Concentration of Glucagon | Evaluated as Area Under the Curve | 0-180 minutes | 
| Concentration of Insulin | Evaluated as Area Under the Curve | 0-180 minutes |
Clinical Study of 18F-FAPI-RGD in Interstitial Lung Disease Associated With Connective Tissue Disease

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to examine clinical utility of 18F-FAPI-RGD PET/CT imaging in evaluating connective tissue disease-associated interstitial lung disease. Participants will undergo clinical evaluation and 18F-FAPI-RGD PET/CT examination.

Detailed Description
-----------------
Interstitial lung disease is an overarching term for a wide range of disorders characterized by inflammation and/ or fibrosis in the lungs. Interstitial lung disease associated connective tissue diseases(CTD-ILD) is one of the most common types.The goal of this study is to explore the feasibility of using 18F-FAPI-RGD, a dual-targeting heterodimeric PET tracer that recognizes both fibroblast activation protein (FAP) and integrin αvβ3 for detecting connective tissue disease associated interstitial lung disease (CTD-ILD), and analyze the relationship between 18F- FAPI-RGD PET/CT images and related parameters of lung function, clinical laboratory indicators and HRCT scores.

Official Title
-----------------
Clinical Study of 18F Labeled Probe Targeting Fibroblast Activating Protein and Integrin avβ3 (FAPI-RGD) in Interstitial Lung Disease Associated With Connective Tissue Disease

Conditions
-----------------
Interstitial Lung Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 and above Patients who have been diagnosed with, or are clinically highly suspected of ILD Patients who have been diagnosed with, or are clinically highly suspected of CTD-ILD Exclusion Criteria: Pregnant or breastfeeding Patients with tumor, other respiratory diseases, and lung surgery Abnormal cardiopulmonary function or mental state, unable tolerate PET/CT

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between clinical indicators and PET/CT results | Correlation of clinical pulmonary function indexes, HRCT, laboratory examination indexes and 18F-FAPI-RGD PET/CT results | 2 months |
Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials

Study Overview
=================
Brief Summary
-----------------
The study seeks to delve into the firsthand experiences of patients diagnosed with rhabdomyosarcoma who partake in a separate clinical trial featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals. The data collected from this study will help improve future outcomes for all rhabdomyosarcoma patients as well as those in under-represented demographic groups.

Official Title
-----------------
Analyzing Engagement Trends in Rhabdomyosarcoma Clinical Trials: A Study of Participation Patterns Among Those Affected by the Disorder

Conditions
-----------------
Rhabdomyosarcoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of rhabdomyosarcoma Considered reliable, able to understand, and willing to perform all study procedures Signed Written Informed Consent Exclusion Criteria: Currently enrolled in, have completed or have discontinued from a clinical trial involving an investigational drug Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study Any serious and/or unstable pre-existing medical disorders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of rhabdomyosarcoma patients who decide to enroll in a clinical trial |  | 3 months | 
| Rate of rhabdomyosarcoma patients who remain in clinical trial to trial completion |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Rhabdomyosarcoma